Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection
- E. Gane*
- , Z. Ben Ari
- , L. Mollison
- , E. Zuckerman
- , R. Bruck
- , Y. Baruch
- , A. Y.M. Howe
- , J. Wahl
- , S. Bhanja
- , P. Hwang
- , Y. Zhao
- , M. N. Robertson
*Corresponding author for this work
- Auckland Clinical Studies
- Sheba Medical Center at Tel Hashomer
- Fremantle Hospital
- Technion-Israel Institute of Technology
- Tel Aviv Sourasky Medical Center
- Merck
Research output: Contribution to journal › Article › peer-review
13
Scopus
citations